

Press information

Rodos Biotarget moves into larger laboratory and production facility

Rodos Biotarget GmbH expands its premises at its Hannover base.

Hannover, 14 September 2016. Rodos Biotarget has moved into the adjoining building in order to further expanding its laboratory and non-GMP production capacities. Please consider Rodos Biotarget's new address. The biopharmaceutical company aims to provide a larger number of customers and collaboration partners with TargoSphere[®] batches to be employed in pilot and non-human efficacy studies. Moreover, new TargoSphere[®] variants furnished with targeting ligands for different target cells will be developed in order to expand the range of applications. Please consider the new address of Rodos Biotarget GmbH.

About Biotarget GmbH

Rodos Biotarget GmbH is a biopharmaceutical company that joins the ranks of industry leadership in nanocarriers for drug delivery. Rodos has developed the versatile TargoSphere[®] platform technology comprising biocompatible and biodegradable nanocarriers. These are designed to achieve enhanced prophylactic and therapeutic approaches against diseases of high and unmet medical need like cancers, chronic infections, autoimmune diseases, and neurological diseases. Rodos Biotarget offers TargoSphere[®] to the pharmaceutical industry as a "construction kit": Specific additives and components of the nanocarriers can be tailored to suit the respective medical objective. The spherical body can be tuned to prolong blood circulation and/or sustained release of the drug payload. Targeting ligands located on the nanocarrier's surface permit specific delivery of the drug within close proximity to target cells and/or allow for the selective uptake of encapsulated actives into such cells. Rodos nanocarriers aim to improve a drug's pharmacokinetics, pharmacodynamics, and safety profile, and they also allow for line and label extensions. Rodos pushes the commercialization of its patented technology platform with two in-house therapeutic applications: TargoBiotics[™] for the treatment of intracellular bacterial infections, and TargoVir[™] for the treatment of devastating viral diseases.

Additional Information: <http://www.biotargeting.eu>

Contact Rodos Biotarget GmbH:

CAUTION: NEW ADDRESS

Rodos Biotarget GmbH
Medical Park Hannover
Feodor-Lynen-Str. 31
D-30625 Hannover / FRG
Tel.: +49 (511) 7273 8835
Fax: +49 (511) 214 7076
m.furch@biotargeting.eu

Contact for Press Representatives:

WeichertMehner Unternehmensberatung für Kommunikation & Co. KG
Mathias Rentsch
Tel.: +49 (351) 5014 0200
mathias.rentsch@weichertmehner.com